PUBLIC MEETING ON DEVICE GENERAL/SPECIFIC INTENDED USES GUIDANCE UNDER CONSIDERATION BY FDA; HIMA FORMING TASK FORCE TO PROVIDE INPUT ON POLICY
This article was originally published in The Gray Sheet
Executive Summary
FDA may seek input on the types of specific intended uses covered by a general device claim through a public meeting, Joseph Sheehan, regulations staff director in FDA's Center for Devices and Radiological Health, said Feb. 4 at a Health Industry Manufacturers Association meeting in Washington, D.C. CDRH plans to publish a guidance on the subject before the Aug. 18 deadline stipulated in the FDA Modernization Act.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.